LAS VEGAS, July 20, 2018 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI), preeminent supplier and manufacturer of hemp-derived phytocannabinoids including cannabidiol (CBD) oil and developer of specialty pharmaceutical therapeutics, announced that it is scheduled to host a conference call to discuss its second quarter 2018 financial results on Wednesday, August 1, 2018 at 1:15pm PT/4:15pm ET.
CV Sciences’ Chief Executive Officer Joseph Dowling will lead the call to provide an operational and financial summary of the second quarter ended June 30, 2018.
|Event: CV Sciences Second Quarter 2018 Financial Results Call|
|Date: Wednesday, August 1, 2018|
|Time: 1:15pm PT/4:15pm ET|
|Telephone access (U.S. and Canada): 877-407-8293|
|Telephone access (International): 201-689-8349|
|Live webcast:www.cvsciences.com under Investors section|
In order to ensure adequate time for any software downloads that may be necessary to listen to the webcast, attendees are encouraged to connect to the website 10-15 minutes prior to the live event.
If you are unable to participate in the call at this time, a replay will be available for 14 days starting on August 1, 2018, at approximately 7:30pm PT/10:30pm ET. To access the replay, please dial 1-877-660-6853 in the U.S. and 1-201-612-7415 for international callers. The conference ID# is 13681926.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
Original Article By: GlobeNewswire
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.